Abstract:Novel biotherapeutic glycoproteins, like recombinant monoclonal antibodies (mAbs) are widely used for the treatment of numerous diseases. The N-glycans attached to the constant region of an antibody have been demonstrated to be crucial for the biological efficacy. Even minor modifications of the N-glycan structure can dictate the potency of IgG effector functions such as the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, we present the development of a glycoengineered CHO-K1 host cell line (HCL), stably expressing β1,4-N-Acetylglucoseaminyltransferase III (GnT-III) and α-mannosidase II (Man-II), for the expression of a-fucosylated antibodies with enhanced Fc-mediated effector function. Glycoengineered HCLs were generated in a two-step strategy, starting with generating parental HCLs by stable transfection of CHO-K1 cells with GnT-III and Man-II. In a second step, parental HCLs were stably transfected a second time with these two transgenes to increase their copy number in the genetic background. Generated glycoengineered CHO-K1 cell lines expressing two different mAbs deliver antibody products with a content of more than 60% a-fucosylated glycans. In-depth analysis of the N-glycan structure revealed that the majority of the Fc-attached glycans of the obtained mAbs were of complex bisected type. Furthermore, we showed the efficient use of FcγRIIIa affinity chromatography as a novel method for the fast assessment of the mAbs a-fucosylation level. By testing different cultivation conditions for the pre-glycoengineered recombinant CHO-K1 clones, we identified key components essential for the production of a-fucosylated mAbs. The prevalent effect could be attributed to the trace element manganese, which leads to a strong increase of a-fucosylated complex- and hybrid-type glycans. In conclusion, the novel pre-glycoengineered CHO-K1 HCL can be used for the production of antibodies with high ratios of a-fucosylated Fc-attached N-glycans. Application of our newly developed FcγRIIIa affinity chromatography method during cell line development and use of optimized cultivation conditions can ultimately support the efficient development of a-fucosylated mAbs.

Cloning and Eukaryotic Expressing of GPI-B7-1 in CHO

Gene Cloning and Construction of Prokaryotic and Plant Expression Vectors of I?L15/PAP Fusion Protein

Construction and Expression of Procaryotic Expression Vector of a Chimeric GPI-B7-1 Cdna

Molecular Cloning of Human IL-7cDNA and Construction of Eukaryotic Vector Expressing Hil-7

Cloning and Expressing of Golgi Protein73 Gene Fragment and Preparation of Monoclonal Antibodies Against the Recombinant Protein

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

Study on the Expression and Immune Enhancement of IL-18-GPI Fused Protein

Construction,expression and Characterization of Recombinant Fusion Protein HSA-PTH(1-34) in Pichia Pastoris

[Cloning of Transmembrane Domain Sequence of EGFR Gene]

Expression of tumor necrosis factor receptor-immunoglobulin G1 Fc fusion protein in glycoengineered Pichia pastoris

Cloning of Hbfgf Cdna and Expression of Recombinant Hbfgf in Pichia Pastoris

High-level expression of recombinant IgG1 by CHO K1 platform

Cloning, Expression and Polyclonal Antibody Preparation of UGRP1 and Its Subcellular Localization

Construction and Identification of Eukaryotic Expression Vector Pcdna3.1 (+)-ABCG2

Cloning of the Gene of a Fusion Protein-Platelet Derived Growth Factor Receptor Binding Domain with Hepatitis B Core Antigen

Cloning of CTB-PROIN fusion gene and its expression in Escherichia coli]

Cloning and High Expression of Hbfgf with a New Strategy.

Expression of CTLA4Ig Fusion Protein in CHO Cells

Cloning and Expressing of HIV-1 Gp41 N and C Peptide Gene

[Cloning of Chinese Banna minipig inbred-line alpha1,3-galactosyltransferase gene and construction of its recombinant eukaryotic expression vector]

Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function